Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
GLYC's Cash to Debt is ranked higher than
88% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. GLYC: No Debt )
GLYC' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
GLYC's Interest Coverage is ranked higher than
71% of the 576 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GLYC: No Debt )
GLYC' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 17.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -50.09
GLYC's Operating margin (%) is ranked higher than
76% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. GLYC: -50.09 )
GLYC' s 10-Year Operating margin (%) Range
Min: -265.19   Max: 24
Current: -50.09

-265.19
24
Net-margin (%) -50.11
GLYC's Net-margin (%) is ranked higher than
76% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. GLYC: -50.11 )
GLYC' s 10-Year Net-margin (%) Range
Min: -265.61   Max: 23.96
Current: -50.11

-265.61
23.96
ROE (%) -20.38
GLYC's ROE (%) is ranked higher than
78% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. GLYC: -20.38 )
GLYC' s 10-Year ROE (%) Range
Min: -137.43   Max: 34.84
Current: -20.38

-137.43
34.84
ROA (%) -18.72
GLYC's ROA (%) is ranked higher than
77% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. GLYC: -18.72 )
GLYC' s 10-Year ROA (%) Range
Min: -89.49   Max: 15.45
Current: -18.72

-89.49
15.45
ROC (Joel Greenblatt) (%) -1582.33
GLYC's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. GLYC: -1582.33 )
GLYC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1849.61   Max: 1623.95
Current: -1582.33

-1849.61
1623.95
» GLYC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

GLYC Guru Trades in

Q1 2014

GLYC Guru Trades in Q1 2014

Steven Cohen 28,648 sh (New)
» More
Q2 2014

GLYC Guru Trades in Q2 2014

George Soros 10,300 sh (New)
» More
Q3 2014

GLYC Guru Trades in Q3 2014

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GLYC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-09-30 Sold Out $7.13 - $9.47 $ 8.343%0
George Soros 2014-06-30 New Buy$6.12 - $16.76 $ 8.34-16%10300
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 86.21
GLYC's Forward P/E is ranked higher than
89% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GLYC: 86.21 )
N/A
P/B 2.70
GLYC's P/B is ranked higher than
87% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. GLYC: 2.70 )
GLYC' s 10-Year P/B Range
Min: 1.81   Max: 5.35
Current: 2.7

1.81
5.35
P/S 7.70
GLYC's P/S is ranked higher than
82% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. GLYC: 7.70 )
GLYC' s 10-Year P/S Range
Min: 7.37   Max: 105.13
Current: 7.7

7.37
105.13
EV-to-EBIT -10.47
GLYC's EV-to-EBIT is ranked lower than
55% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GLYC: -10.47 )
GLYC' s 10-Year EV-to-EBIT Range
Min: -26.2   Max: -3.4
Current: -10.47

-26.2
-3.4
Current Ratio 13.14
GLYC's Current Ratio is ranked higher than
91% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. GLYC: 13.14 )
GLYC' s 10-Year Current Ratio Range
Min: 2.14   Max: 21.83
Current: 13.14

2.14
21.83
Quick Ratio 13.14
GLYC's Quick Ratio is ranked higher than
92% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. GLYC: 13.14 )
GLYC' s 10-Year Quick Ratio Range
Min: 2.14   Max: 21.83
Current: 13.14

2.14
21.83

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.80
GLYC's Price/Net Cash is ranked higher than
96% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. GLYC: 2.80 )
GLYC' s 10-Year Price/Net Cash Range
Min: 2.31   Max: 5.65
Current: 2.8

2.31
5.65
Price/Net Current Asset Value 2.80
GLYC's Price/Net Current Asset Value is ranked higher than
95% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. GLYC: 2.80 )
GLYC' s 10-Year Price/Net Current Asset Value Range
Min: 2.31   Max: 5.65
Current: 2.8

2.31
5.65
Price/Tangible Book 2.70
GLYC's Price/Tangible Book is ranked higher than
90% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. GLYC: 2.70 )
GLYC' s 10-Year Price/Tangible Book Range
Min: 2.28   Max: 5.54
Current: 2.7

2.28
5.54
Price/Median PS Value 1.10
GLYC's Price/Median PS Value is ranked higher than
86% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. GLYC: 1.10 )
GLYC' s 10-Year Price/Median PS Value Range
Min: 0.88   Max: 10.89
Current: 1.1

0.88
10.89
Earnings Yield (Greenblatt) -9.80
GLYC's Earnings Yield (Greenblatt) is ranked higher than
70% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. GLYC: -9.80 )
GLYC' s 10-Year Earnings Yield (Greenblatt) Range
Min: -9.9   Max: 0
Current: -9.8

-9.9
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:GKO.Germany,
» More Articles for GLYC

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest percentage increases Mar 04 2015
GlycoMimetics Announces Publication of Phase 2 Data for Rivipansel in Sickle Cell Disease Mar 03 2015
9:02 am GlycoMimetics announces the publication of results from a randomized, placebo-controlled... Mar 03 2015
GlycoMimetics Announces Publication of Phase 2 Data for Rivipansel in Sickle Cell Disease Mar 03 2015
GlycoMimetics to Present at Two Investor Conferences in March Feb 26 2015
GlycoMimetics to Present at Two Investor Conferences in March Feb 26 2015
HTML PDF Feb 16 2015
GlycoMimetics to Present at 17th Annual BIO CEO & Investor Conference Feb 03 2015
GlycoMimetics Highlights Potential Therapeutic Benefits of Its Novel E-Selectin Antagonist at 56th... Dec 09 2014
GlycoMimetics Highlights Potential Therapeutic Benefits of Its Novel E-Selectin Antagonist at 56th... Dec 09 2014
University of Michigan to Study GlycoMimetics' GMI-1271 as Potential Treatment for Serious... Dec 04 2014
University of Michigan to Study GlycoMimetics’ GMI-1271 as Potential Treatment for Serious... Dec 04 2014
HTML PDF Dec 01 2014
4 Biotech Catalyst Stocks to Buy With 60% to 100% Upside Potential Nov 20 2014
GlycoMimetics Announces Positive Top-Line Results from Phase 1 Study of GMI-1271 in Healthy... Nov 17 2014
GlycoMimetics Announces Positive Top-Line Results from Phase 1 Study of GMI-1271 in Healthy... Nov 17 2014
GlycoMimetics to Present at Stifel Healthcare Conference 2014 Nov 12 2014
GlycoMimetics to Present at Stifel Healthcare Conference 2014 Nov 12 2014
GlycoMimetics E-selectin and Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting Nov 06 2014
GlycoMimetics E-selectin and Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting Nov 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK